Argos Therapeutics, Inc. Identifies Topical Formulation for Prolonged Graft Survival in Corneal Transplants
Published: Aug 15, 2013
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
DURHAM, N.C., Aug. 15, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of therapies that modulate the immune system to treat cancer, infectious diseases, transplant rejection, autoimmune and inflammatory diseases, today announced the publication of key findings on its soluble recombinant human CD83 protein (sCD83) in cornea transplants. The study, conducted in rodents, demonstrates that CD83 can modulate the immune system and promote graft survival.
Help employers find you! Check out all the jobs and post your resume.
DURHAM, N.C., Aug. 15, 2013 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of therapies that modulate the immune system to treat cancer, infectious diseases, transplant rejection, autoimmune and inflammatory diseases, today announced the publication of key findings on its soluble recombinant human CD83 protein (sCD83) in cornea transplants. The study, conducted in rodents, demonstrates that CD83 can modulate the immune system and promote graft survival.
Help employers find you! Check out all the jobs and post your resume.